Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Dec;32(12):1849-56.
doi: 10.1016/j.leukres.2008.05.014. Epub 2008 Jun 27.

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

Clive S Zent  1 , Charla R Secreto, Betsy R LaPlant, Nancy D Bone, Timothy G Call, Tait D Shanafelt, Diane F Jelinek, Renee C Tschumper, Neil E Kay
Affiliations
Clinical Trial

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

Clive S Zent et al. Leuk Res. 2008 Dec.

Abstract

The mechanism of cytotoxicity of alemtuzumab and rituximab in chronic lymphocytic leukemia (CLL) is not well understood. We obtained fresh CLL cells from early-intermediate stage high-risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance. Alemtuzumab had minimal direct cytotoxicity but caused significant complement dependent cytotoxicity (CDC) although a subpopulation of CLL cells had intrinsic resistance. Rituximab had no direct cytotoxicity and caused minimal CDC in cells from most patients. These data suggest that CDC has a therapeutic role in patients treated with alemtuzumab and that measures to decrease resistance to CDC could increase efficacy.

PubMed Disclaimer

Figures

1
1. Alemtuzumab and rituximab are not toxic to CLL cells in culture
CLL cells at 2 × 106/ml were cultured with either alemtuzumab (10 µg/ml)(A), rituximab (20 µg/ml)(R), or alemtuzumab and rituximab (A&R) at the same concentrations. Viable cell (trypan blue negative) counts were evaluated every 24 hours for 72 hours. These data demonstrate that cells cultured with rituximab have identical survival to control cells (CON) cultured in AIM V medium. Cells cultured with alemtuzumab or alemtuzumab and rituximab have slightly lower survival.
2
2. Alemtuzumab complement dependent cytotoxicity (CDC) induces rapid cytotoxicity of CLL cells
CLL cells at a concentration of 2 × 106/ml were treated with alemtuzumab (10µg/ml) and 10% human serum as a source of complement. Cytotoxicity was determined by counting the number of viable cells (trypan blue negative) 1 hour after treatment. These values were normalized using the counts in control cell cultures treated with complement only. These studies showed that alemtuzumab CDC (A&C) killed a median of 67% (range 15 – 100%) of the CLL cells from 27 patients within 1 hour. The cells surviving CDC did not have an increased rate of death during the subsequent 23 hours. Addition of rituximab to alemtuzumab (A&R&C) did not significantly increase CDC (p = 0.20).
3
3. The subpopulation of CLL cells that survive alemtuzumab CDC remains viable for 72 hours
CLL cells at 2 × 106/ml were treated with alemtuzumab (10µg/ml) and 10% human serum as a source of complement and cultured for 72 hours. These assays showed that cells surviving initial CDC caused by alemtuzumab (A&C) or the combination of alemtuzumab and rituximab (A&R&C) had the same survival as cells treated with complement alone (C).
4
4. Cells treated with MoAb and complement had increased membrane iC3 binding
Membrane bound iC3b was measured in CLL cells by flow cytometry with an anti-iC3b antibody. Control CLL cells in AIM V medium stained with anti-iC3b antibody are shown in panel a. Addition of 10% serum (4U/ml complement) resulted in a modest increase in MFI (from 20 to 36)(panel b). Addition of both rituximab and complement (panel c) resulted in an increase in MFI to 201. In this experiment, the highest level of iC3b was measured in cells surviving treatment with alemtuzumab and complement (panel d) which had a MFI of 1129.
See this image and copyright information in PMC

References

    1. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 2001;92:1325–1330. - PubMed
    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–276. - PMC - PubMed
    1. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47:1738–1746. - PubMed
    1. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an Effective Therapy for Chronic Lymphocytic Leukemia with p53 Mutations and Deletions. Blood. 2004;103:3278–3281. - PubMed
    1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234. - PubMed

Publication types

MeSH terms